Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS
Completed
- Conditions
- Older Cancer Patients
- Registration Number
- NCT02662998
- Lead Sponsor
- General Hospital Groeninge
- Brief Summary
The aim of this study is to validate uHear™, an iOS-based tool, as a screening tool to detect significant hearing impairment as part of a comprehensive geriatric assessment in patients aged 70 years and older. The pass or fail screening cut-off is defined as having two or more consecutive hearing grades starting from the moderate-severe threshold zone ranging from 0.5 - 2.0 kHz.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
- Patients should have reached the age of 70 or more at enrolment
- Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible
- Patients should be fluent in Dutch or French
- Patients must receive their primary oncology care in the participating hospital
- Patients should be cognitively capable of performing the audiology assessment
- Patients should be scheduled to receive a CGA
- Patients should have signed informed consent
Exclusion Criteria
- Patients who do not match the above inclusion criteria
- Patients presenting with clinically diagnosed Meniere's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss
- Patients who already have a hearing aid or a previously diagnosed hearing loss
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Validation of uHear™ with its new scoring method as a screening tool to detect hearing loss in older cancer patients baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
General Hospital Groeninge, Cancer Center
🇧🇪Kortrijk, Belgium